Skip to main content

Advertisement

Log in

Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The use of infusional chemotherapy, especially in an ambulatory setting, absolutely requires that the individual agents remain stable in solution at room temperature and that the drugs be compatible. Because of this, investigation of the chemical compatibilities of chemotherapeutic drug combinations given in the same infusion solution is quite important especially if the drugs are to remain in solution for long periods. Thus, the visual and chemical compatibility of irinotecan and epirubicin in the same infusion solution were investigated using both reference standards and pharmaceutical dosage forms. No sign of incompatibility was observed upon visual examination by means of effervescence, pH change, precipitation and colour change. But a chemical incompatibility was observed using a spectrophotometric method in the spectra of irinotecan-HCl and epirubicin-HCl. The molar ratio of epirubicin-HCl/irinotecan-HCl at which the interaction reached a maximum was found to be 2:1. The chemical interaction occurred immediately after admixing and no visual or spectral change was noticed for 24 h after the interaction had occurred. It is concluded that these drugs are chemically incompatible. While the applicability of these two drugs in combination is investigated in further pharmacological studies, their chemical interaction should also be a consideration. The positive or negative contribution of this interaction to the pharmacological effect of the combination might be of importance, and therefore should be investigated in further clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Chen X, Oza AM, Kusenda Z, et al (2003) Phase I study of cisplatin, irinotecan and epirubicin administered every two weeks in patients with advanced solid tumours. Br J Cancer 89(4):617–624

    Article  CAS  PubMed  Google Scholar 

  2. Chollet DF, Goumaz L, Renard A, et al (1998) Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high performance liquid chromatography. J Chromatogr B 718:163–175

    CAS  Google Scholar 

  3. Cohen MH, Johnston-Early A, Hood MA, et al (1985) Drug precipitation within IV tubing: a potential hazard of chemotherapy administration. Cancer Treat Rep 69:1325–1326

    CAS  PubMed  Google Scholar 

  4. Ellence (1999) Epirubicin hydrochloride injection, revised package insert. Pharmacia & Upjohn, Perth

    Google Scholar 

  5. Hwang JJ, Marshall JL, Rizvi N (2003) Combined inhibition of topoisomerases: a phase 1 study of irinotecan and epirubicin. Oncology 17 [Suppl 5]:S46–S51

    Google Scholar 

  6. Lacy LF, Armstrong LL, Goldman MP (2002/2003) Drug information handbook with international index. Lexi-comp, Hudson, Cleveland, pp 472–474

    Google Scholar 

  7. Living Proof (2000) Camptosar, Pharmacia & Upjohn, Yakult, Daiichi

  8. Marshall JL, Baidas S, Rizvi N (2002) Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report. Oncology New York (Huntingt) 16:17–19

    Google Scholar 

  9. McRae MP, King JC (1976) Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 33:1010–1013

    CAS  PubMed  Google Scholar 

  10. Parfitt K, Sweetman SC, Blake PS, Parsons AV (1999) The complete drug reference, 32nd edn. Pharmaceutical Press, London, p 543

    Google Scholar 

  11. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235–2242

    Article  CAS  PubMed  Google Scholar 

  12. Radford JA, Margison JM, Swindell R, Mad MJ, Wilkinson PM, Thatcher N (1991) The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J Cancer Res Clin Oncol 117 [Suppl IV]:S151–S156

    Article  Google Scholar 

  13. Rothenberg ML, Blanke CD (1999) Topoisomerase I inhibitors in the treatment of colorectal cancer. Colorectal cancer: past accomplishments and future directions II. Semin Oncol 26:632–639

    CAS  Google Scholar 

  14. Trissel LA, Parks NPT, Santiago NM (1991) Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 48:2186–2189

    CAS  PubMed  Google Scholar 

  15. USP (1997) Drug information for the health care professional, vol I. 17th edn. United States Pharmacopeia Convention, Rockville, MD, pp 3040–3050

    Google Scholar 

  16. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19(6):670–686

    CAS  PubMed  Google Scholar 

  17. Wilkinson K (2001) Irinotecan hydrochloride. Clin J Oncol Nurs 5(4):179–180, 184

    CAS  PubMed  Google Scholar 

  18. Williams DA, Lokich JA (1994) Review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions. Cancer Chemother Pharmacol 31:171–181

    Article  Google Scholar 

  19. Wood MJ, Irwin WJ, Scott DK (1990) Stability of daunorubicin, doxorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 15:279–289

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank our Head of Department Prof. Dr. Emre Dölen for supporting us with his deep experience and knowledge, Marmara University Scientific Research Found for financial support, Pharmacia & Upjohn, Italy, and Maria Teresa Perversi for continuous support concerning reference standards, Pharmacia & Upjohn-Turkey, and Berhan Mısırlıgil, Aventis Pharma-Turkey for generous support during our work, and Dr. Çigdem Arı, Marmara University Hospital Oncology Department, and Associate Prof. Dr. Serdar Turhal, Dr. Mahmut Gümüş and Ayla Karaman for providing the pharmaceutical forms of the two drugs, and Aventis Pharma-France for the irinotecan reference standard.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Filiz Arioz Ozdemir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozdemir, F.A., Anilanmert, B. & Pekin, M. Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 56, 529–534 (2005). https://doi.org/10.1007/s00280-004-0990-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0990-z

Keywords

Navigation